Davila-Garcia_1997_J.Pharmacol.Exp.Ther_282_445

Reference

Title : [125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors - Davila-Garcia_1997_J.Pharmacol.Exp.Ther_282_445
Author(s) : Davila-Garcia MI , Musachio JL , Perry DC , Xiao Y , Horti A , London ED , Dannals RF , Kellar KJ
Ref : Journal of Pharmacology & Experimental Therapeutics , 282 :445 , 1997
Abstract :

An analog of epibatidine (EB) was synthesized with an iodine atom in the 2 position of the pyridyl ring. This analog, (+/-)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo[2.2.1]heptane (IPH), as well as its two stereoisomers, displayed high affinity for neuronal nicotinic receptors; therefore, radioiodinated IPH, [125I]IPH, was synthesized with specific radioactivities consistently > 1000 Ci/mmol, and its properties as a radioligand for neuronal nicotinic receptors were evaluated. The characteristics of [125I]IPH binding in tissue homogenates appeared to be virtually identical to those reported for [3H]epibatidine binding; but the high specific radioactivity of [125I]IPH greatly facilitated measurements of nicotinic receptors in tissues with relatively low receptor densities and/or where tissues are in limited supply. Autoradiography with [125I]IPH provided clear localization of nicotinic receptors in brain and adrenal gland after film exposure times of < or = 2 days. We conclude that [125I]IPH will be a very useful radioligand for the study of neuronal nicotinic receptors in brain and in peripheral ganglia.

PubMedSearch : Davila-Garcia_1997_J.Pharmacol.Exp.Ther_282_445
PubMedID: 9223586

Related information

Citations formats

Davila-Garcia MI, Musachio JL, Perry DC, Xiao Y, Horti A, London ED, Dannals RF, Kellar KJ (1997)
[125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors
Journal of Pharmacology & Experimental Therapeutics 282 :445

Davila-Garcia MI, Musachio JL, Perry DC, Xiao Y, Horti A, London ED, Dannals RF, Kellar KJ (1997)
Journal of Pharmacology & Experimental Therapeutics 282 :445